Journal article

Selective laser trabeculoplasty versus topical medication as initial glaucoma treatment: the glaucoma initial treatment study randomised clinical trial

Ghee Soon Ang, Eva K Fenwick, Marios Constantinou, Alfred Tau Liang Gan, Ryan Eyn Kidd Man, Robert J Casson, Eric A Finkelstein, Ivan Goldberg, Paul R Healey, Konrad Pesudovs, Sutha Sanmugasundram, Jing Xie, Rachel McIntosh, Jonathan Jackson, Anthony Wells, Andrew White, Keith Martin, Mark J Walland, Jonathan G Crowston, Ecosse Luc Lamoureux

British Journal of Ophthalmology | BMJ PUBLISHING GROUP | Published : 2020


BACKGROUND/AIMS: To determine if selective laser trabeculoplasty (SLT) is superior to topical medication as a first-line treatment for glaucoma on quality of life (QoL) and clinical outcomes. METHODS: In this international, longitudinal, multisite randomised controlled trial, treatment naïve mild-to-moderate primary open angle or exfoliation glaucoma patients were randomised 1:1 to SLT or topical medication. Glaucoma-specific QoL (primary outcome) was measured using the Glaucoma Outcomes Assessment Tool (GOAT; 342 items, 12 domains). Secondary outcomes included rate of successful intraocular pressure (IOP) reduction (>25% reduction from baseline) and presence of ocular surface disease includ..

View full abstract


Awarded by Australian National Health and Medical Research Council (NHMRC)

Awarded by NHMRC Research Fellowship

Awarded by NHMRC Practitioner Fellowship

Awarded by NHMRC Early Career Fellowship

Funding Acknowledgements

This Randomised Controlled Trial was funded by a Project Grant from the Australian National Health and Medical Research Council (NHMRC #1009844-EL as PI). CERA receives operational infrastructure support from the Victorian Government. Last and corresponding author ELL was funded by a NHMRC Research Fellowship (#1045280) and co-last author JGC was funded by an NHMRC Practitioner Fellowship (#529915) and by the Dorothy Adele Edols Charitable Trust. Co-main author EKF was funded by an NHMRC Early Career Fellowship (#1072987).